3Heiker JT. Vaspin(serpinA12) in obesity, insulin resistance, and inflammation [J]. J Pept Sci, 2014,20(5) :299-306.
4Zhang B, Peng W, Li H, et al. Plasma vaspin concentrations are decreased in acute coronary syndrome, but unchanged in patients without coronary lesions [J]. Clin Biochem, 2013,46 (15) : 1520-1525.
5Li HL, Peng WH, Cui ST, et al. Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris[J]. Clin Chem Lab Med, 2011,49(9):1547- 1554.
6Kadoglou NP, Gkontopoulos A, Kapelouzou A, et al. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study [J]. Clin Chim Acta, 2011,412(1-2): 48-52.
7Phalitakul S, Okada M, Hara Y, et al. Vaspin prevents TNF- or-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-κB and PKC0 activation in cultured rat vascular smooth muscle cells [J]. Pharmacol Res, 2011,64(5) :493-500.
8Phalitakul S, Okada M, Hara Y, et al. A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-indueed migration of vascular smooth muscle cells [J].Biochem Biophys Res Commun, 2012,423(4) :844-849.
9Liu B, Che W, Yan H, et al. Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease [J]. Intern Med, 2013,52 (24) : 2715-2719.
10Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey[J]. Drug Des Devel Ther,2011,5:325-380.
6Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广（译）,王淑敏（译）,胡大一（校）.极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志（中文版）,2006,25(4):215-223. 被引量：346
